Ultragenyx announces positive 24-week data from first cohort of phase 1/2 study of DTX401
Ultragenyx Pharmaceutical announced positive longer-term top-line safety and efficacy data from the first, lowest dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for treatment of glycogen storage disease type Ia. February 21, 2019